NCT07016802View on ClinicalTrials.gov

A Clinical Study of GenSci134 in Healthy Male Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

April 13, 2026

Study Completion Date

April 13, 2026

Conditions
Healthy Volunteers
Interventions
DRUG

GenSci134

only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.

DRUG

GenSci134 Placebo

only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.

DRUG

Recombinant Human Growth Hormone Injection (Norditropin®)

A single dose of 0.2 mg/day, administered once daily (QD) for 28 consecutive days.

Trial Locations (1)

100083

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY